0001193125-20-216447.txt : 20200811 0001193125-20-216447.hdr.sgml : 20200811 20200811170358 ACCESSION NUMBER: 0001193125-20-216447 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200806 ITEM INFORMATION: Shareholder Nominations Pursuant to Exchange Act Rule 14a-11 FILED AS OF DATE: 20200811 DATE AS OF CHANGE: 20200811 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CRYO CELL INTERNATIONAL INC CENTRAL INDEX KEY: 0000862692 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MISC HEALTH & ALLIED SERVICES, NEC [8090] IRS NUMBER: 223023093 STATE OF INCORPORATION: DE FISCAL YEAR END: 1130 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-23386 FILM NUMBER: 201093201 BUSINESS ADDRESS: STREET 1: 700 BROOKER CREEK BLVD STREET 2: SUITE 1800 CITY: OLDSMAR STATE: FL ZIP: 34677 BUSINESS PHONE: 813-749-2104 MAIL ADDRESS: STREET 1: 700 BROOKER CREEK BLVD STREET 2: SUITE 1800 CITY: OLDSMAR STATE: FL ZIP: 34677 8-K 1 d81044d8k.htm 8-K 8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of

The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 6, 2020

 

 

CRYO-CELL INTERNATIONAL, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   0-23386   22-3023093

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

700 Brooker Creek Blvd., Suite 1800, Oldsmar, FL   34677
(Address of principal executive offices)   (Zip Code)

Registrant’s telephone number, including area code:  (813) 749-2100

Not applicable

(Former name or former address, if changed since last report)

 

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading Symbol(s)

  

Name of each exchange

on which registered

Common Stock, $0.01 par value   CCEL   OTCQB

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 

 

Item 5.08.

Shareholder Director Nominations.

The Board of Directors of Cryo-Cell International, Inc. (the “Company”) has fixed September 22, 2020 as the date for the 2020 Annual Meeting of Stockholders of the Company (the “Annual Meeting”), and has fixed August 21, 2020 as the record date for determining stockholders entitled to notice of and to vote at the Annual Meeting. Stockholders intending to present business or director nominations at the Annual Meeting must submit the notice required by Article II, Section 3 of the Company’s Bylaws (with respect to business other than director nominations) or Article II, Section 10 of the Company’s Bylaws (with respect to director nominations) no later than the 10th calendar day following the day on which public disclosure of the date of the Annual Meeting is first made, which date of public disclosure is August 11, 2020.

A copy of the Company’s Bylaws, as amended, is included as Exhibit 3.1 to the Current Report on Form 8-K filed with the United States Securities and Exchange Commission on December 11, 2018.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

CRYO-CELL INTERNATIONAL, INC.

Dated:  August 11, 2020

  

By: 

  

/s/  David Portnoy

   

David Portnoy

   

Chairman and Co-Chief Executive Officer